Loading...

Brilliant Violet 785™ anti-human CD14 Antibody

Pricing & Availability
Clone
M5E2 (See other available formats)
Regulatory Status
RUO
Workshop
III 329
Other Names
LPS receptor
Isotype
Mouse IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
M5E2_BV785_CD14_Antibody_FC_091712
Human peripheral blood monocytes were stained with CD14 (clone M5E2) Brilliant Violet 785™.
  • M5E2_BV785_CD14_Antibody_FC_091712
    Human peripheral blood monocytes were stained with CD14 (clone M5E2) Brilliant Violet 785™.
See Brilliant Violet 785™ spectral data
Cat # Size Price Quantity Check Availability Save
301839 25 tests £163
Check Availability


Need larger quantities of this item?
Request Bulk Quote
301840 100 tests £278
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD14 is a 53-55 kD glycosylphosphatidylinositol (GPI)-linked membrane glycoprotein also known as LPS receptor. CD14 is expressed at high levels on monocytes and macrophages, and at lower levels on granulocytes. Some dendritic cell populations such as interfollicular dendritic cells, reticular dendritic cells, and Langerhans cells have also been reported to express CD14. As a high-affinity receptor for LPS, CD14 is involved in the clearance of gram-negative pathogens, and in the upregulation of adhesion molecules and expression of cytokines in monocytes and neutrophils.

Product Details
Technical Data Sheet (pdf)

Product Details

Reactivity
Human,Cynomolgus,Rhesus
Antibody Type
Monoclonal
Host Species
Mouse
Immunogen
Full-length human CD14 protein
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 785™ under optimal conditions.
Concentration
Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Brilliant Violet 785™ excites at 405 nm and emits at 785 nm. The bandpass filter 780/60 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 785™ is a trademark of Sirigen Group Ltd.


Learn more about Brilliant Violet™.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser
Violet Laser (405 nm)
Application Notes

The M5E2 antibody inhibits monocyte activation and cytokine production induced by LPS. Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen sections, blocking of LPS stimulation4, and immunofluorescence microscopy5. Clone M5E2 is not recommended for immunohistochemical staining of formalin-fixed paraffin-embedded sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 301861 and 301862).

Application References

(PubMed link indicates BioLegend citation)
  1. McMichael A, et al. 1987. Leucocyte Typing III. Oxford University Press. New York.
  2. Knapp W, et al. Eds. 1989. Leucocyte Typing IV. Oxford University Press. New York. (IHC-F)
  3. Schlossman S, et al. Eds. 1995. Leucocyte Typing V. Oxford University Press. New York.
  4. Power CP, et al. 2004. J. Immunol. 173:5229. (Block)
  5. Williams KC, et al. 2001. J. Exp. Med. 193:905.
  6. Iwamoto S, et al. 2007. J. Immunol. 179:1449. (FC) PubMed
  7. Santer DM, et al. 2010. J. Immunol. 485:4739. PubMed
  8. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
  9. Zizzo G, et al. 2012. J. Immunol. 189:3508. PubMed
  10. Stoeckius M, et al. 2017. Nat. Methods. 14:865. (PG)
  11. Peterson VM, et al. 2017. Nat. Biotechnol. 35:936. (PG)
Product Citations
  1. Darrah PA, et al. 2019. NPJ Vaccines. 4:21. PubMed
  2. Querfeld C, et al. 2018. Cancer Immunol Res. 6:900. PubMed
  3. Alcántara‐Hernández M et al. 2017. Immunity. 47(6):1037-1050 . PubMed
  4. Leylek R, et al. 2019. Cell Rep. 29:3736. PubMed
  5. Tran TM, et al. 2020. Immunity. 51(4):750-765. PubMed
  6. Ferrando–Martinez S, et al. 2019. JHEP Rep. 0.159722222. PubMed
  7. Leylek R, et al. 2020. Cell Rep. 32:108180. PubMed
  8. Smedley J, et al. 2016. PLoS One. 11: 0157535. PubMed
  9. Roura S, et al. 2016. Lab Invest. 10.1038/labinvest.2016.100. PubMed
  10. Kristensen A, et al. 2017. Cytokine. 10.1016/j.cyto.2017.02.017. PubMed
  11. Stone D, et al. 2021. Hum Gene Ther. 32:96. PubMed
  12. Vierboom MPM, et al. 2021. Cell Reports Medicine. 2(1):100185. PubMed
  13. Lu Q, et al. 2021. Immunity. 54(6):1304-1319.e9. PubMed
  14. Pantelyushin S, et al. 2021. Cancers (Basel). :13. PubMed
  15. Wang LT, et al. 2020. Immunity. 53:733. PubMed
  16. Pinto SM, et al. 2021. Front Immunol. 12:679458. PubMed
  17. Qing G, et al. 2021. Front Cell Dev Biol. 9:761300. PubMed
  18. Chakraborty S, et al. 2022. Sci Transl Med. . PubMed
  19. Yu KK, et al. 2021. JCI Insight. 6:. PubMed
  20. van Doorn CLR, et al. 2021. Front Immunol. 12:712021. PubMed
  21. Gagne M, et al. 2022. Cell. 185:113. PubMed
  22. Yoshida R, et al. 2022. Cancer Res. :. PubMed
  23. Estep BK, et al. 2022. iScience. 25:105544. PubMed
  24. García-García A, et al. 2023. Bioact Mater. 24:174. PubMed
  25. Meyer S, et al. 2023. Cell Rep. 42:111995. PubMed
  26. Bohrer AC, et al. 2022. Cell Rep. 40:111144. PubMed
  27. Ribeiro MS, et al. 2023. Methods Mol Biol. 2618:289. PubMed
  28. Lafôrets F, et al. 2023. iScience. 26:106514. PubMed
RRID
AB_2561366 (BioLegend Cat. No. 301839)
AB_2563425 (BioLegend Cat. No. 301840)

Antigen Details

Structure
GPI-linked membrane glycoprotein, 53-55 kD
Distribution

Monocytes, macrophages, granulocytes (low)

Function
LPS receptor, clearance of Gram-negative pathogens
Ligand/Receptor
LPS
Cell Type
Granulocytes, Macrophages, Monocytes, Neutrophils
Biology Area
Cell Biology, Immunology, Innate Immunity, Neuroinflammation, Neuroscience
Molecular Family
CD Molecules
Antigen References

1. Stocks S, et al. 1990. Biochem. J. 268:275.
2. Wright S, et al. 1990. Science 249:1434.

Gene ID
929 View all products for this Gene ID
UniProt
View information about CD14 on UniProt.org
Go To Top Version: 4    Revision Date: 11/05/2013

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account